'Right To Try' Bill Contradicts US FDA’s Mission, Former Official Says
Executive Summary
Heading into the user fee reauthorization cycle, it seems inevitable that some form of federal 'right to try' legislation will tag-along for the ride. The recently departed head of the Office of New Drugs is among those who thinks the innocuous-sounding bill is a very bad idea.
You may also be interested in...
Trump On Right-to-Try: Gottlieb's 'Heading It Up'?
Curious comment by president could place US FDA Commissioner in tough spot balancing his boss' priorities with his and staff's concerns about pending right-to-try legislation.
Not Quite FDARA Add-Ons: Right-To-Try, Patient Experience, Opioid Measures Also Clear US Senate
Senate passage of the FDA user fee package without amendments was enabled by unanimous consent votes on controversial right-to-try legislation that is toned down from its initial version, as well as two other bills.
'Right To Try' And PDUFA VI: Patient Advocates, Industry Fight Senate Add-On
Given that 'right to try' is intended to be a patient-centered proposal, patient organizations are a strong voice in opposition, working behind the scenes to revise – or entirely exclude – the legislation as part of the user fee package. But the bill also has powerful advocates among Senate Republicans and in the Trump Administration.